vimarsana.com

Latest Breaking News On - Cutaneous dermatomyositis disease area - Page 1 : vimarsana.com

Emerging Therapies Foretell New Era for Cutaneous Disorders

Analogous to the early 2000s when treatment options for psoriasis jumped, the same may be true now for treating cutaneous autoimmune disorders.

United statesAnthony fernandezDrug administrationAmerican academy of dermatologyCleveland clinicCutaneous lupus erythematosus disease areaSeverity indexCutaneous dermatomyositis disease areaNew england journalAmerican academySystemic lupus erythematosus sle erythaematosusCutaneous lupus erythematosus erythaematosusBiologic therapyInterferon betaFn betaInterferon beta

Teen With Severe, Recalcitrant Dermatomyositis Seeks New Option

Treatment-resistant juvenile dermatomyositis resolved by targeting elevated interferon-beta

United statesRuth ann vleugelsKate kneiselHarvard medical schoolRheumatologic dermatology societyBoston childrenCutaneous dermatomyositis disease areaSeverity index activityRheumatologic dermatology

Data Support Interferon Beta as Therapeutic Target

Response rates in a phase 2 trial of a novel therapy for skin-predominant dermatomyositis were favorable in patients failed by at least one prior standard therapy, prompting plans for a phase 3 trial.

United statesHensin tsaoPaul nghiemAaron mangoldUniversity of washingtonAmerican academy of dermatologyLesion center at massachusettsAmerican academyMayo clinicCutaneous dermatomyositis disease areaSeverity indexPigmented lesion centerMassachusetts general hospitalBiologic therapyInterferon betaFn beta

Lenabasum Studied for Refractory Cutaneous Dermatomyositis

TUESDAY, Oct. 11, 2022 (HealthDay News) Lenabasum is well tolerated for the treatment of amyopathic dermatomyositis, according to a phase 2 study published online Oct. 1 in the Journal of Investigative Dermatology. Victoria P. Werth, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues evaluated the safety and efficacy

United statesUniversity of pennsylvania perelman school medicineCorbus pharmaceuticalsHealthday newsPennsylvania perelman schoolCutaneous dermatomyositis disease areaSeverity index

IVIg Proves Effective for Dermatomyositis in Phase 3 Trial

Prior to this trial, intravenous immune globulin had not been fully studied for the treatment of dermatomyositis.

United statesUniversity of texas southwestern medical centerDavid fiorentinoAnthonya amatoRohit aggarwalKathrynh daoDivision of rheumatologyDrug administrationHarvard medical schoolDivision of rheumatic diseasesUniversity of pittsburghStanford health careNew england journalRheumatic diseasesTexas southwestern medical centerClinical immunology

vimarsana © 2020. All Rights Reserved.